Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Taylor Langston

Nurse Practitioner Deland, FL Nurse Practitioner

NPI 1336495134 CMS profile 11087139

810 N Spring Garden Ave Ste 100, Deland, FL 32720

Open in the dashboard

General payments

$8,512

400 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Taylor Langston of Deland, FL is reported in the CMS Open Payments database as having received $8,512 across 400 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,091 140
2024 General $352 18
2023 General $1,336 45
2022 General $2,366 124
2021 General $1,367 73

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Taylor Langston
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Taylor Langston were reported at $3,091. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Taylor Langston Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $1,367 $135 $40–$426 $132
2022 $2,366 $152 $48–$470 $149
2023 $1,336 $166 $54–$529 $160
2024 $352 $173 $55–$556 $164
2025 $3,091 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Novartis Pharmaceuticals Corporation $1,207 54 payments
  2. Janssen Biotech, Inc. $667 36 payments
  3. Merck Sharp & Dohme Corporation $408 18 payments
  4. AstraZeneca Pharmaceuticals LP $389 18 payments
  5. Daiichi Sankyo Inc. $348 13 payments
  6. Incyte Corporation $335 17 payments
  7. Astellas Pharma US Inc $285 10 payments
  8. Genzyme Corporation $242 11 payments
  9. Celgene Corporation $224 10 payments
  10. Bayer HealthCare Pharmaceuticals Inc. $223 12 payments
  11. Other $4,184 201 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $8,072 395 payments
  2. Long term medical supply or device loan $299 3 payments
  3. Education $141 2 payments
Products named General payments · program years 2021–2025
  1. KEYTRUDA $385 17 payments
  2. KISQALI $375 23 payments
  3. REBLOZYL $326 10 payments
  4. JAKAFI $284 15 payments
  5. IMBRUVICA $281 15 payments
  6. LIBTAYO $268 12 payments
  7. IMFINZI $256 11 payments
  8. ENHERTU $239 8 payments
  9. Lenvima $217 12 payments
  10. RYBREVANT $199 11 payments
  11. Other $7,017 353 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 20 billing codes

Paid by Medicare

$18,807

Medicare's payments for the services billed

Medicare patients

52

Average age 76

Services billed

775

31 women, 21 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 65%
Diabetes 62%
Ischemic heart disease 62%
Chronic kidney disease 62%
Heart failure 52%
COPD 50%
Atrial fibrillation 44%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 17 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Lenvima
  • Eisai Inc. $38
$38 — —
SCEMBLIX
  • Novartis Pharmaceuticals Corporation $33
$33 — —
BRUKINSA
  • BeiGene USA, Inc. $30
$30 — —
VONJO
  • Sobi, Inc $26
$26 — —
Fabhalta
  • Novartis Pharmaceuticals Corporation $24
$24 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 17 in the dashboard with a free account

Records

400 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record